The experience of the coronavirus epidemic development observation shows that CT and X-Ray studies are the most important methods for the coronavirus infection comprehensive diagnostics. Severe cases of coronavirus and mortality associated with it are closely related to the development of viral and bacterial (secondary) pneumonia, which is why these methods have become widely used for patients with suspected coronavirus infection and suspected lung damage caused by it. The results of these studies play a crucial role in patients treatment and the workload of radiologists significantly increases as a result.
Intellogic LLC, the Russian developer of the leading analysis and processing of medical images platform with the use of artificial intelligence Botkin.AI, has quickly developed and integrated into its platform a product for the pneumonia detection. The company expects that this will reduce risks and remit the possible consequences of COVID-19. Due to the complicated epidemiological circumstances and the need for quick reaction on virus spread, Intellogic has decided to provide access to the new platform product for all medical organizations involved in the diagnosis and treatment of patients with COVID-19 for free.
First pilot projects using the new platform functionality are getting started in several regions of Russia these days. Due to the risk of coronavirus COVID-19 further spread, the regional healthcare authorities have decided to test a new Botkin.AI product in order to reduce the risk of missing coronavirus pneumonia symptoms. In future, the new product can be used to control the dynamical observation of pneumonia, including patients with the coronavirus COVID-19. It is planned to implement such projects in different regions of Russia and outbound at an early date.
Intellogic LLC is a Skolkovo resident, the Scientific Advisory Board of the company is led by the president of the Russian Society of Radiologists, Professor Valentin Sinitsyn. The platform allows & assists radiologists to analyze digital X-Ray, CT and digital Mammography studies. The company has already integrated the platform in more than 10 regions of Russian Federation, CIS countries, and is currently implementing a number of international projects. The results of the technology for the analysis of pneumonia preliminary testing which are published by the company in scientific articles, show the analysis accuracy of more than 99%, which is one of the best results in the world at the moment.
Our company pays significant attention to the research and development of new healthcare products using artificial intelligence technologies. We are very pleased that our efforts helped us to launch a new important project to reduce the risks and possible consequences of the coronavirus COVID-19 at a very short period of time. We look forward to receiving positive results of its testing in practical healthcare and are ready to implement similar projects in regions of Russia as soon as possible. Due to the difficult epidemiological situation, we provide access to the new functionality of our platform free of charge until May 2020. We hope that our products will qualitatively assist radiologists, and most importantly, will help patients.